PCMA’s report  adds new evidence pushing back on that line of thought. According to the study, drugmakers raised list prices even in therapeutic classes where rebates are typically low. In multiple sclerosis, for instance, the estimated average list price rose 125% between 2011 and 2016. Net prices increased even more, by 156%, during the same time period — indicating the list price growth was not fueled by a large uptick in rebate level.